Novavax, Inc. (NASDAQ:NVAX) Holdings Lifted by Northern Trust Corp

Northern Trust Corp raised its holdings in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,451,715 shares of the biopharmaceutical company's stock after acquiring an additional 83,503 shares during the period. Northern Trust Corp owned approximately 0.91% of Novavax worth $11,672,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Susquehanna Fundamental Investments LLC bought a new stake in Novavax during the 4th quarter valued at $2,761,000. Virtus ETF Advisers LLC raised its stake in Novavax by 77.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 38,765 shares of the biopharmaceutical company's stock valued at $312,000 after acquiring an additional 16,881 shares in the last quarter. Dauntless Investment Group LLC bought a new stake in Novavax during the 4th quarter valued at $698,000. Syon Capital LLC bought a new stake in Novavax during the 4th quarter valued at $128,000. Finally, Hsbc Holdings PLC raised its stake in Novavax by 69.4% during the 4th quarter. Hsbc Holdings PLC now owns 17,931 shares of the biopharmaceutical company's stock valued at $144,000 after acquiring an additional 7,344 shares in the last quarter. Institutional investors own 53.04% of the company's stock.

Novavax Trading Up 2.5%

Shares of NASDAQ NVAX traded up $0.18 during mid-day trading on Thursday, reaching $7.29. The company had a trading volume of 7,095,345 shares, compared to its average volume of 7,343,279. The stock has a market cap of $1.18 billion, a PE ratio of -3.23, a P/E/G ratio of 2.85 and a beta of 3.21. The company has a 50-day moving average price of $6.63 and a two-hundred day moving average price of $7.85. Novavax, Inc. has a 1-year low of $5.01 and a 1-year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.71 by $2.22. The company had revenue of $666.66 million during the quarter, compared to analyst estimates of $204.08 million. The business's revenue was up 610.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) earnings per share. On average, research analysts expect that Novavax, Inc. will post -1.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NVAX. JPMorgan Chase & Co. cut their target price on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday, May 9th. BTIG Research assumed coverage on Novavax in a research note on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective on the stock. Finally, TD Cowen raised Novavax to a "hold" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $19.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.